[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasopressin-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasopressin-deficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100423076","phase-1-effects-of-intranasal-oxytocin-in-patients-with-arginine-vasopressin-deficiency-100423076",false,"NCT04789148","Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency","Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency - A Pilot Study","Inclusion Criteria:\n\n* Age 18 and above\n* Arginine-vasopressin deficiency\n* Normal FT4 or T4\n* Normal serum\u002Fplasma sodium\n* Stable hormone replacement\n\nExclusion Criteria:\n\n* Active substance use disorder within the last 6 months\n* History of psychosis\n* Suicidal behavior and\u002For active suicidal ideation with plan and\u002For intent, e.g., suicidal ideation of type 4 or type 5 as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS), in the last month\n* Medication changes within 4 weeks of enrollment or planned medication changes during the study\n* History of chronic nasal obstruction or local pathology in nostril pathway which, in the opinion of the investigator, would prevent appropriate nasal administration of the study drug.\n* History of cardiac disease, including arrhythmias, coronary heart disease, coronary artery spasms, valvular heart disease, hypertrophic cardiomyopathy (hypertension is not exclusionary)\n* History of chronic kidney disease stage III and above\n* History of liver cirrhosis\n* Pregnancy or breastfeeding within the last 8 weeks\n* Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only)\n* Any significant illness, condition, drug or medical device that the Investigator determines could interfere with study participation, data collection, or safety","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B).\n\nFollowing a screening visit to determine eligibility, participants will return for three main study visits in Part A. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior.\n\nIn Part A, thirty participants will be equally randomized to one of six possible groups:\n\n1. 6 IU oxytocin - 24 IU oxytocin - placebo\n2. 6 IU oxytocin - placebo - 24 IU oxytocin\n3. 24 IU oxytocin - 6 IU oxytocin - placebo\n4. 24 IU oxytocin - placebo - 6 IU oxytocin\n5. placebo - 6 IU oxytocin - 24 IU oxytocin\n6. placebo - 24 IU oxytocin - 6 IU oxytocin\n\nFollowing completion of the Part A crossover portion of the study, in Part B participants may also choose to continue participation in an optional, randomized, double-blind, placebo-controlled substudy of intranasal oxytocin 6 IU or placebo three times a day for two weeks, followed by assessments of emotional behavior.",[26],"Vasopressin Deficiency",[28,29,30,31,32,33,34],"Hypopituitarism","posterior pituitary","oxytocin","psychopathology","anxiety","depressive symptoms","socioemotional functioning","RECRUITING","2025-09-10",{"date":38,"type":39},"2025-09-16","ACTUAL",{"date":36,"type":39},{"date":42,"type":20},"2026-06",{"name":44,"class":45},"Elizabeth Austen Lawson","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":73},"100548590","registry-of-patients-in-shock-treated-with-vasopressin-100548590","NCT06422975","Registry of Patients in Shock Treated With Vasopressin","Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care Units","Inclusion Criteria:\n\n* Any patient over 18 years of age who is in shock and requires the administration of vasoconstrictors, to whom vasopressin is administered in the operating theatre and\u002For critical care unit, according to best clinical practice.\n\nExclusion Criteria:\n\n* Non-consent by patient\u002Flegal representatives",{"count":55,"type":20},500,"90 Days","OBSERVATIONAL","Arginine-vasopressin (AVP) is a non-catecholaminergic hormone produced in the hypothalamus and released into the circulation via the neurohypophysis. It has different actions depending on the receptors through which it acts: V1 (vasoconstriction, platelet aggregation, efferent arteriole constriction of the renal glomerulus, glycogenolysis); V2 (water reabsorption, release of von Willebrand factor and factor VIII); V3 (increased cortisol and insulin).\n\nSeptic shock is the most common cause of vasoplegic shock and its management includes control of the focus, early antibiotic therapy, volume resuscitation, vasopressor therapy, support of various organ dysfunctions, as well as monitoring and follow-up.\n\nThe Surviving Sepsis Campaign (a global initiative to improve sepsis management) recommends noradrenaline as the first line of vasopressor therapy and early addition of AVP as a second line rather than further up-titration of noradrenaline when signs of hypoperfusion persist, through its action primarily on V1.\n\nThe rationale for its use in septic shock would be:\n\n* endogenous vasopressin deficiency present in septic shock;\n* as a catecholamine-sparing strategy, reducing the side effects of catecholamines;\n* its potential nephroprotective effect;\n* its use should be early.\n\nThe uncertainties surrounding the use of AVP in septic shock and other types of shock are many, hence the need for this registry.",[60,61,62,26],"Vasopressin Causing Adverse Effects in Therapeutic Use","Shock","Vasopressor Adverse Reaction",[64,61],"Vasopressin","2024-07-11",{"date":67,"type":39},"2024-07-15",{"date":69,"type":39},"2024-07-09",{"date":42,"type":20},{"name":72,"class":45},"Hospital Universitario 12 de Octubre",24]